I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 456362868 US, on the date shown below in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Alexandria, VA 22313-1450.

d: September 28, 2006 Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inde Patent Application of: Dolores SCHENDEL et al.

Serial No.: 10/665,111

Filing Date: September 16, 2003

SEMI-ALLOGENIC ANTI-TUMOUR For:

VACCINE WITH HLA HAPLO-

IDENTICAL ANTIGEN-PRESENTING

CELLS

Examiner: K. Canella

Group Art Unit: 1643

SUPPLEMENTAL INFORMATION DISCLOSURE **STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. A copy of the non-patent literature is submitted herewith. The Examiner is requested to make these documents of record.

This Supplemental Information Disclosure Statement is submitted:
With the application; accordingly, no fee or separate requirements are required.
Before the mailing of a first Office Action after the filing of a Request for Continued
Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97
(e)(1) has been provided.

10/04/2006 RMEBRAHT 00000077 031952

	Within three months of the application filing date or before mailing of a first Office Action			
	on the	merits; accordingly, no fee or separate requirements are required. However, if		
	applica	able, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.		
\boxtimes	After r	receipt of a first Office Action on the merits but before mailing of a final Office Action		
	or Not	ice of Allowance.		
		A fee is required. A check in the amount of is enclosed.		
	\boxtimes	A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to		
		this submission in duplicate.		
		A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is		
		believed to be due.		
	After 1	mailing of a final Office Action or Notice of Allowance, but before payment of the		
	issue f	ee.		
		A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the		
		amount of is enclosed.		
		A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal		
		form (PTO/SB/17 is attached to this submission in duplicate.)		

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petition and/or other

fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing <u>559412000200</u>.

Dated: September 28, 2006

Respectfully submitted,

Micia J. Hager

Registration No.: 44,140 MORRISON & FOERSTER LLP

755 Page Mill Road

Palo Alto, California 94304-1018

(650) 813-4296

SEP 2 9 2006

ubstitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known				
Application Number	10/665,111			
Filing Date	September 16, 2003			
First Named Inventor	Dolores SCHENDEL			
Art Unit	1643			
Examiner Name	K. Canella			
Attorney Docket Number	559412000200			

	U.S. PATENT DOCUMENTS					
F	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
Examiner Initials*		Number-Kind Code ² (if known)				
	1.	US-4,415,553-A	11-15-1983	Zhabilov et al.		
 	2.	US-4,568,542-A	02-04-1986	Kronenberg		
	3.	US-4,789,658-A	12-06-1988	Yoshimoto et al.		
	4.	US-4,877,611-A	10-31-1989	Cantrell		
	5.	US-5,156,841-A	10-20-1992	Rapp		
	6.	US-5,290,551-A	03-01-1994	Berd		
	7.	US-5,582,831-A	12-10-1996	Shinitzky		

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁰

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
	8.	Kugler, A. et al. (September 2003). RETRACTION: "Regression of Human Metastatic Renal Cell Carcinoma After Vaccination with Tumor Cell-Dendritic Cell Hybrids," <i>Nature Medicine</i> 9(9):1221.				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date
Signature	Considered

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.